Diagnostic efficacy of the secretin stimulation test for the Zollinger-Ellison syndrome: an intra-individual comparison using different dosages in patients and controls Abstract #17

Introduction: The diagnosis of Zollinger-Ellison syndrome is suspected in patients with symptoms of gastric acid hypersecretion, i.e., peptic ulcer disease, malabsorption or diarrhea, or with elevated fasting serum gastrin levels. However, symptoms can be masked by the use of proton pump inhibitors and fasting serum gastrin values are not always conclusive. Therefore, the secretin stimulation test is advocated as the principal diagnostic tool to identify the Zollinger-Ellison syndrome.
Aim(s): To investigate whether a higher dose of secretin would lead to higher serum gastrin increases, resulting in better sensitivity and specificity of the secretin stimulation test to identify Zollinger-Ellison patients.
Materials and methods: We analyzed 57 sequential secretin stimulation tests, using both 0.26 µg/kg and 0.78 µg/kg secretin, performed in 13 Zollinger-Ellison syndrome patients and 12 controls. First, we investigated the most optimal criterion for defining a positive secretin stimulation test. By intra-individual comparison, we investigated which dose of secretin resulted in the highest diagnostic efficacy for identifying the Zollinger-Ellison syndrome. Lastly, we applied the determined criterion for a positive secretin stimulation test in a confirmative set of 98 secretin stimulation tests using the low dose of secretin in 21 Zollinger-Ellison syndrome patients and 39 controls to validate our initial results.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Patricia Kuiper

To read results and conclusion, please login ...

Further abstracts you may be interested in

#848 Zollinger-Ellison Syndrome: The Esophageal Stricture as a Rare and Severe Complication
Introduction: Zollinger-Ellison Syndrome (ZES) is caused by tumoral hypersecretion of gastrin, inducing gastric hyperchlorhydria and complicated peptic ulcer disease. Esophageal strictures are rare in ZES, due to early PPI treatment.
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: Claudio Pasquali
#267 Plasma Somatostatin: Gastrin Ratio Improves the Diagnosis of Gastrinoma
Introduction: Fasting gastrin alone is inadequate for diagnosis of gastrinoma. Diagnosis requires confirmation of low gastric pH. Low gastric pH is associated with increased numbers of D (somatostatin) cells.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Radha Ramachandran
#277 Metastatic Gastrinoma Co-secreting PTHrP and ACTH
Introduction: Metastatic gastrinoma is occasionally associated with tumor secretion of functioning peptides, resulting in additional syndromes.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Richard W Carroll
#135 The importance of endoscopic ultrasound in detecting recurrent gastrinoma in a case of MEN 1
Introduction: Approximately 25-30% of patients have gastrinomas as part of the inherited syndrome Multiple Endocrine Neoplasia 1 (MEN 1). Gastrinomas occur in the pancreas, duodenum or peripancreatic lymph nodes. Diagnosis is made by clinical history, gastroscopy, and measurement of serum gastrin, gastric juice pH, CT scan, endoscopic ultrasound (EUS) and somatostatin receptor scintigraphy (SRS). Localization of gastrinomas in patients with MEN 1 is challenging due to their small size, frequent duodenal location, and multiplicity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Laura De Marinis
#1012 Efficacy of Lanreotide Autogel in MEN1-Related Gastrinoma: A Case Series
Introduction: GEP NETs, especially gastrinomas, occur in 40-70% of MEN1 patients and represent the main cause of death in these patients.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Laura De Marinis
Keywords: MEN1, SSA, gastrin